VanEck Pharmaceutical ETF (NASDAQ:PPH) Shares Sold by Nadler Financial Group Inc.

Nadler Financial Group Inc. cut its stake in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 30.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,995 shares of the company’s stock after selling 1,340 shares during the quarter. Nadler Financial Group Inc.’s holdings in VanEck Pharmaceutical ETF were worth $244,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. raised its holdings in shares of VanEck Pharmaceutical ETF by 462.4% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 18,148 shares of the company’s stock worth $1,477,000 after purchasing an additional 14,921 shares during the last quarter. Private Client Services LLC acquired a new stake in shares of VanEck Pharmaceutical ETF during the 4th quarter worth approximately $298,000. GSA Capital Partners LLP increased its holdings in shares of VanEck Pharmaceutical ETF by 12.6% during the 3rd quarter. GSA Capital Partners LLP now owns 13,210 shares of the company’s stock valued at $1,055,000 after purchasing an additional 1,480 shares in the last quarter. Allworth Financial LP purchased a new stake in VanEck Pharmaceutical ETF during the fourth quarter worth $28,000. Finally, LPL Financial LLC grew its position in VanEck Pharmaceutical ETF by 60.8% during the third quarter. LPL Financial LLC now owns 65,749 shares of the company’s stock valued at $5,251,000 after buying an additional 24,850 shares during the period.

VanEck Pharmaceutical ETF Trading Up 0.3 %

Shares of VanEck Pharmaceutical ETF stock traded up $0.26 during trading hours on Friday, reaching $86.78. The stock had a trading volume of 176,789 shares, compared to its average volume of 126,243. The stock’s 50 day moving average is $88.73 and its 200 day moving average is $83.61. VanEck Pharmaceutical ETF has a twelve month low of $74.05 and a twelve month high of $91.16. The firm has a market capitalization of $498.12 million, a PE ratio of 20.57 and a beta of 0.72.

VanEck Pharmaceutical ETF Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Friday, April 5th. Shareholders of record on Tuesday, April 2nd were issued a $0.5328 dividend. The ex-dividend date of this dividend was Monday, April 1st.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.